Larvol Delta - DUALTHRUST-Vebreltinib-Plus-Furmonertinib-in-Patients-With-EGFRmutated-Advanced-Nonsmall-Cell-Lung-Cancer-and-High-PDL1-Expression

vebreltinib (APL-101) - Apollomics

Ivesa (firmonertinib) - Allist, ArriVent

http://clinicaltrials.gov/ct2/show/NCT07655622

Jun 19, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next